Complete Remission of Anaplastic Thyroid Carcinoma after Concomitant Treatment with Docetaxel and Radiotherapy

被引：6

作者：

Abe, Ichiro ^{[1
,2
]}

Karasaki, Satoko ^{[1
]}

Matsuda, Yayoi ^{[1
]}

Sakamoto, Shohei ^{[1
]}

Nakashima, Torahiko ^{[3
]}

Yamamoto, Hidetaka ^{[4
]}

Kawate, Hisaya ^{[1
]}

Ohnaka, Keizo ^{[1
]}

Nakashima, Hisashi ^{[5
]}

Kobayashi, Kunihisa ^{[2
]}

Oda, Yoshinao ^{[4
]}

Nomura, Masatoshi ^{[1
]}

Takayanagi, Ryoichi ^{[1
]}

机构：

[1] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Higashi Ward, Maidashi 3-1-1, Fukuoka 8128582, Japan

[2] Fukuoka Univ, Chikushi Hosp, Dept Endocrinol & Diabet Mellitus, Fukuoka 8188502, Japan

[3] Kyushu Univ, Grad Sch Med Sci, Dept Otorhinolaryngol, Higashi Ward, Fukuoka 8128582, Japan

[4] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ward, Fukuoka 8128582, Japan

[5] Haradoi Hosp, Dept Internal Med, Higashi Ward, Fukuoka 8138588, Japan

来源：

CASE REPORTS IN ENDOCRINOLOGY | 2015年 / 2015卷

关键词：

D O I：

10.1155/2015/726085

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anaplastic thyroid carcinoma (ATC) although rare is the most lethal form of thyroid cancer. The mortality rate for ATC is very high, with a median survival time of only 5 months; the survival rate at 1 year after diagnosis is <20%. Management of ATC is extremely difficult and rife with uncertainties. Herein, we describe a 75-year-old woman who presented with ATC and was successfully treated using concomitant treatment with docetaxel and high-dose radiotherapy. This case appears to be the first to have been reported in the literature involving complete remission of ATC confirmed by autopsy, suggesting the therapeutic potential of this combination.

引用

页数：4

共 16 条

[1] Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study [J].

Cohen, Ezra E. W. ;

Rosen, Lee S. ;

Vokes, Everett E. ;

Kies, Merrill S. ;

Forastiere, Arlene A. ;

Worden, Francis P. ;

Kane, Madeleine A. ;

Sherman, Eric ;

Kim, Sinil ;

Bycott, Paul ;

Tortorici, Michael ;

Shalinsky, David R. ;

Liau, Katherine F. ;

Cohen, Roger B. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4708-4713

[2]

Cooney MM, 2006, J CLIN ONCOL, V24, p300S

[3] BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis [J].

Gauchotte, Guillaume ;

Philippe, Christophe ;

Lacomme, Stephanie ;

Leotard, Brigitte ;

Wissler, Marie-Pierre ;

Allou, Lila ;

Toussaint, Bruno ;

Klein, Marc ;

Vignaud, Jean-Michel ;

Bressenot, Aude .

PATHOLOGY, 2011, 43 (05) :447-452

[4]

Gilliland FD, 1997, CANCER-AM CANCER SOC, V79, P564, DOI 10.1002/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO

[5]

2-0

[6] Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature [J].

Granata, Roberta ;

Locati, Laura ;

Licitra, Lisa .

CURRENT OPINION IN ONCOLOGY, 2013, 25 (03) :224-228

[7]

Ha H. T., 2009, J CLIN ONCOL, V27

[8] CHECKPOINTS - CONTROLS THAT ENSURE THE ORDER OF CELL-CYCLE EVENTS [J].

HARTWELL, LH ;

WEINERT, TA .

SCIENCE, 1989, 246 (4930) :629-634

[9] Anaplastic thyroid carcinoma - Treatment outcome and prognostic factors [J].

Kebebew, E ;

Greenspan, FS ;

Clark, OH ;

Woeber, KA ;

McMillan, A .

CANCER, 2005, 103 (07) :1330-1335

[10]

Nagaiah G, 2009, J CLIN ONCOL, V27

← 1 2 →